Agomelatine for SAD: Decent Evidence, Not a Cure-All

The evidence for agomelatine in seasonal affective disorder is modest but real, especially for late-winter episodes, though it’s not clearly better than bupropion or SSRIs for most people.

Most of the data comes from a handful of randomized trials, plus the fact that agomelatine’s mechanism—melatonin receptor agonism plus serotonin 2C antagonism—makes theoretical sense for SAD. The circadian disruption people get in late winter (oversleeping, fatigue, craving carbs) is exactly the profile agomelatine targets. Studies show it improves depressive symptoms and seems to help with the hypersomnia and low energy that classic SSRIs sometimes don’t touch.

But here’s the catch: head-to-head comparisons with bupropion or fluoxetine are scarce. Bupropion has way more evidence for preventing and treating SAD, especially the “atypical” symptoms like oversleeping and overeating. SSRIs are well-studied too. Agomelatine’s main advantages are fewer sexual side effects and potentially better sleep architecture. Its disadvantages: it’s not approved in the US (available in Europe and elsewhere